GW Pharmaceuticals (NASDAQ:GWPH): Buy Rating was Maintained by Research Analysts at Bank of America; with PT of $200.

June 27, 2018 - By Ronnie Lemelle

Reiterated GW Pharmaceuticals (NASDAQ:GWPH) Rating.

In analysts report revealed to clients by Bank of America’s investment analysts, GW Pharmaceuticals (NASDAQ:GWPH) had it’s stock Rating reiterated to Buy. On Tuesday, 26 June it has $200 or 43.53 % PT that would indicate a potential upside move.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

In total 5 analysts cover GW Pharma (NASDAQ:GWPH). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 10 are the (NASDAQ:GWPH)’s analyst reports since December 28, 2017 according to StockzIntelligence Inc. In Tuesday, June 26 report Goldman Sachs initiated the stock with “Buy” rating. On Monday, June 25 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Cantor Fitzgerald. On Tuesday, February 6 Leerink Swann maintained GW Pharmaceuticals plc (NASDAQ:GWPH) with “Outperform” rating. On Tuesday, June 26 Bank of America maintained GW Pharmaceuticals plc (NASDAQ:GWPH) with “Buy” rating. On Tuesday, April 17 the firm earned “Buy” rating by Cantor Fitzgerald. On Monday, February 5 the firm earned “Buy” rating by Cantor Fitzgerald. The stock rating was maintained by Cowen & Co with “Buy” on Wednesday, April 18. The stock rating was maintained by Leerink Swann with “Buy” on Thursday, December 28. On Tuesday, January 23 Leerink Swann maintained GW Pharmaceuticals plc (NASDAQ:GWPH) with “Buy” rating. On Tuesday, February 6 the rating was maintained by Bank of America with “Buy”.

Ticker’s shares touched $139.34 during the last trading session after 4.89% change.GW Pharmaceuticals plc has 682,486 shares volume, 54.71% up from normal. GWPH is uptrending and has moved 49.14% since June 27, 2017. GWPH outperformed the S&P500 by 36.57%.

Investors expect GW Pharmaceuticals plc (NASDAQ:GWPH)’s quarterly earnings on August, 6., as reported by Faxor. This year’s EPS analyst estimate is anticipated to be $-2.39. That is 15.46 % down compareed to $-2.07 EPS for last year. -23.40 % EPS growth is what analysts predict. $-3.12 EPS was reported for previous quarter.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.The company has $3.93 billion market cap. The firm operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development.Last it reported negative earnings. The Company’s lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

For more GW Pharmaceuticals plc (NASDAQ:GWPH) news published recently go to: Seekingalpha.com, Benzinga.com, Benzinga.com, Nasdaq.com or Fool.com. The titles are as follows: “D-Day Approaches For GW Pharma” published on June 20, 2018, “420 Investor: Cannabis Drug Approval Creates ‘Logic Issue’ For The US Government” on June 26, 2018, “GW Pharma’s Epidiolex Becomes First Cannabis-Based FDA-Approved Drug” with a publish date: June 25, 2018, “Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher …” and the last “Why Marijuana Stock GW Pharmaceuticals Gained 21% in May” with publication date: June 14, 2018.

GW Pharmaceuticals plc (NASDAQ:GWPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.